{"id":1012222,"date":"2026-10-21T16:04:40","date_gmt":"2026-10-21T20:04:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/"},"modified":"2026-10-21T16:04:40","modified_gmt":"2026-10-21T20:04:40","slug":"biocryst-to-report-third-quarter-2026-financial-results-on-november-4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/","title":{"rendered":"BioCryst to Report Third Quarter 2026 Financial Results on November 4"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">RESEARCH TRIANGLE PARK, N.C., Oct.  21, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N_N0ZVpMhddQLMVexTGTj9XwRZJPVEydxKjonf4OydwNBRchHUqRlZv0dc9uexJSjEyZASnCRoGA8DLUFFsTxe0WKfLEippuAZ-UXpsKZzD8oKN0d2g_UgHK4QSDYaGF\" rel=\"nofollow\" target=\"_blank\">BioCryst Pharmaceuticals, Inc.<\/a> (Nasdaq:\u00a0BCRX) today announced that the company will report its third quarter 2026 financial results on Wednesday, November 4, 2026.<\/p>\n<p align=\"justify\">BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.<\/p>\n<p align=\"justify\">A live webcast and replay of the call will be available online in the investors section of the company website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kChc9Io9-pUxrIamU9N_BHyK6ydco82T1zh6TIlcqV7TNY_l1iAz1kW8EUF2ckekbMZkyz6Y-dUAVt0JHkdE33Bgl4UsIqsul07G86s2D_M=\" rel=\"nofollow\" target=\"_blank\">www.biocryst.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About BioCryst Pharmaceuticals <\/strong>\n      <\/p>\n<p align=\"justify\">BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO\u00ae (berotralstat), the first oral, once-daily plasma kallikrein inhibitor and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kChc9Io9-pUxrIamU9N_BJb3vhbx4p9wkkX--BG2j2wyOa3GhoiZZQXVklh4BcKK1JZRY4VuNh-tDOBrARtSvD60vn9FnPbsfJwJKmgtonk=\" rel=\"nofollow\" target=\"_blank\">www.biocryst.com<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q-OwyFUY9E_By8diZ5WYRMRp-_wHMabKQv2TIlzGm6L38_VnJCVNdjYHFfhNK22DxQg76eTEMrwFBK3EbyG5NZkqkm982UF0705TKoKKJ-JOFYqFV497IYb1DgrBfwcS\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">BCRXW<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <u>Contact:<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Investors:<\/strong><br \/>\n        <br \/>investorrelations@biocryst.com<\/p>\n<p align=\"justify\">\n        <strong>Media:<\/strong><br \/>\n        <br \/>media@biocryst.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0OTcyMyM3OTA2NTU2IzIwMDQ3MTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDNlOTAzMzktNGJmYS00ZTlmLTlkYWItZGM3NWI5NGZiNTE0LTEwMTYyODctMjAyNi0xMC0yMS1lbg==\/tiny\/BioCryst-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) &#8212; BioCryst Pharmaceuticals, Inc. (Nasdaq:\u00a0BCRX) today announced that the company will report its third quarter 2026 financial results on Wednesday, November 4, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioCryst to Report Third Quarter 2026 Financial Results on November 4&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1012222","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioCryst to Report Third Quarter 2026 Financial Results on November 4 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioCryst to Report Third Quarter 2026 Financial Results on November 4 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) &#8212; BioCryst Pharmaceuticals, Inc. (Nasdaq:\u00a0BCRX) today announced that the company will report its third quarter 2026 financial results on Wednesday, November 4, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized &hellip; Continue reading &quot;BioCryst to Report Third Quarter 2026 Financial Results on November 4&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-21T20:04:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0OTcyMyM3OTA2NTU2IzIwMDQ3MTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioCryst to Report Third Quarter 2026 Financial Results on November 4\",\"datePublished\":\"2026-10-21T20:04:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\\\/\"},\"wordCount\":174,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0OTcyMyM3OTA2NTU2IzIwMDQ3MTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\\\/\",\"name\":\"BioCryst to Report Third Quarter 2026 Financial Results on November 4 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0OTcyMyM3OTA2NTU2IzIwMDQ3MTQ=\",\"datePublished\":\"2026-10-21T20:04:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0OTcyMyM3OTA2NTU2IzIwMDQ3MTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0OTcyMyM3OTA2NTU2IzIwMDQ3MTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioCryst to Report Third Quarter 2026 Financial Results on November 4\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioCryst to Report Third Quarter 2026 Financial Results on November 4 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/","og_locale":"en_US","og_type":"article","og_title":"BioCryst to Report Third Quarter 2026 Financial Results on November 4 - Market Newsdesk","og_description":"RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) &#8212; BioCryst Pharmaceuticals, Inc. (Nasdaq:\u00a0BCRX) today announced that the company will report its third quarter 2026 financial results on Wednesday, November 4, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized &hellip; Continue reading \"BioCryst to Report Third Quarter 2026 Financial Results on November 4\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-21T20:04:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0OTcyMyM3OTA2NTU2IzIwMDQ3MTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioCryst to Report Third Quarter 2026 Financial Results on November 4","datePublished":"2026-10-21T20:04:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/"},"wordCount":174,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0OTcyMyM3OTA2NTU2IzIwMDQ3MTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/","name":"BioCryst to Report Third Quarter 2026 Financial Results on November 4 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0OTcyMyM3OTA2NTU2IzIwMDQ3MTQ=","datePublished":"2026-10-21T20:04:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0OTcyMyM3OTA2NTU2IzIwMDQ3MTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0OTcyMyM3OTA2NTU2IzIwMDQ3MTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biocryst-to-report-third-quarter-2026-financial-results-on-november-4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioCryst to Report Third Quarter 2026 Financial Results on November 4"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1012222"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012222\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1012222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1012222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1012222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}